| Literature DB >> 33244168 |
Congwen Wei1, Luming Wan1, Qiulin Yan1,2, Xiaolin Wang1, Jun Zhang1, Xiaopan Yang1, Yanhong Zhang1, Chen Fan3, Dongyu Li1, Yongqiang Deng4, Jin Sun1, Jing Gong1,2, Xiaoli Yang5, Yufei Wang5, Xuejun Wang6, Jianmin Li1, Huan Yang1, Huilong Li1, Zhe Zhang1, Rong Wang1, Peng Du1, Yulong Zong7, Feng Yin7, Wanchuan Zhang8, Nan Wang8, Yumeng Peng1, Haotian Lin1, Jiangyue Feng1, Chengfeng Qin4, Wei Chen1, Qi Gao9, Rui Zhang10, Yuan Cao11, Hui Zhong12.
Abstract
Responsible for the ongoing coronavirus disease 19 (COVID-19) pandemic, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects host cells through binding of the viral spike protein (SARS-2-S) to the cell-surface receptor angiotensin-converting enzyme 2 (ACE2). Here we show that the high-density lipoprotein (HDL) scavenger receptor B type 1 (SR-B1) facilitates ACE2-dependent entry of SARS-CoV-2. We find that the S1 subunit of SARS-2-S binds to cholesterol and possibly to HDL components to enhance viral uptake in vitro. SR-B1 expression facilitates SARS-CoV-2 entry into ACE2-expressing cells by augmenting virus attachment. Blockade of the cholesterol-binding site on SARS-2-S1 with a monoclonal antibody, or treatment of cultured cells with pharmacological SR-B1 antagonists, inhibits HDL-enhanced SARS-CoV-2 infection. We further show that SR-B1 is coexpressed with ACE2 in human pulmonary tissue and in several extrapulmonary tissues. Our findings reveal that SR-B1 acts as a host factor that promotes SARS-CoV-2 entry and may help explain viral tropism, identify a possible molecular connection between COVID-19 and lipoprotein metabolism, and highlight SR-B1 as a potential therapeutic target to interfere with SARS-CoV-2 infection.Entities:
Year: 2020 PMID: 33244168 DOI: 10.1038/s42255-020-00324-0
Source DB: PubMed Journal: Nat Metab ISSN: 2522-5812